极光抑制剂
极光激酶
激酶
极光A激酶
癌症研究
癌变
极光激酶B
癌症
丝氨酸苏氨酸激酶
有丝分裂
生物
蛋白激酶A
细胞生物学
遗传学
细胞周期
主轴装置
细胞
细胞分裂
作者
Min Yan,Chunli Wang,Bin He,Mengying Yang,Man‐Li Tong,Zi‐Jie Long,Bing Liu,Fei Peng,Lingzhi Xu,Yan Zhang,Dapeng Liang,Hetian Lei,Subrata Sen,Keith W. Kelley,Eric W.‐F. Lam,Boquan Jin,Quentin Liu
摘要
Abstract The Aurora kinase family is comprised of three serine/threonine kinases, Aurora‐A, Aurora‐B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis, whereas Aurora‐C executes unique roles in meiosis. Overexpression or gene amplification of Aurora kinases has been reported in a broad range of human malignancies, pointing to their role as potent oncogenes in tumorigenesis. Aurora kinases therefore represent promising targets for anticancer therapeutics. A number of Aurora kinase inhibitors (AKIs) have been generated; some of which are currently undergoing clinical evaluation. Recent studies have unveiled novel unexpected functions of Aurora kinases during cancer development and the mechanisms underlying the anticancer actions of AKIs. In this review, we discuss the most recent advances in Aurora‐A kinase research and targeted cancer therapy, focusing on the oncogenic roles and signaling pathways of Aurora‐A kinases in promoting tumorigenesis, the recent preclinical and clinical AKI data, and potential alternative routes for Aurora‐A kinase inhibition.
科研通智能强力驱动
Strongly Powered by AbleSci AI